Renal cancer, also known as kidney cancer, is cancer that starts in kidney cells. Different types of renal cancer develop in different ways, which means that these diseases have different long-term outcomes and require being staged and treatment in different ways. The two most common types of renal cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC, also known as urothelial cell carcinoma) of the renal pelvis. Renal cell carcinoma accounts for about 80% of primary renal cancer, most of the remaining are renal cell carcinoma. Creative Biolabs provides a number of IVD antibodies development services for renal cancer diagnosis.
In many cases, renal cancer is found early when the tumor is small and confined to the kidney, making it easier to treat. In recent years, the incidence of renal cancer appears to be increasing. One reason may be that imaging techniques such as CT scanning are being used more often, which may lead to unexpected discoveries of more kidney cancer.
Symptoms
Early renal cancer rarely causes signs or symptoms. There are currently no routine tests to screen for renal cancer without symptoms. In the later stages, signs and symptoms of renal cancer may include:
Types & Conditions
Different types of renal cancer develop in different ways, which means that these diseases have different long-term outcomes and require being staged and treatment in different ways. The two most common types of renal cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC, also known as urothelial cell carcinoma) of the renal pelvis.
Renal cell carcinoma (RCC) - a type of renal cancer that originates from the proximal tubule lining. RCC is the most common type of kidney cancer in adults. The initial treatment is usually partial or complete removal of the affected kidneys. People with renal cell cancer often have advanced disease when discovered. The initial symptoms of RCC usually include abdominal pain, weight loss, abdominal or abdominal mass, fever, blood in the urine, high blood pressure, night sweats and general feeling of discomfort. When RCC metastases, the survival rate will be greatly reduced. RCC most commonly spread to the lungs, adrenal, lymph nodes, liver, brain or bones. Immunotherapy and targeted therapies have improved the prospects for metastatic RCC.
Transitional cell carcinoma (TCC) - also known as Urothelial carcinoma (UCC), is cancer that usually occurs in the urinary system. It originates from the transitional epithelium of the tissue on the inner surface of these hollow organs. TCC is the second most common type of renal cancer but only accounts for 5-10% of all primary renal malignancies. It is the most common bladder and ureter cancer, urinary tract cancer and urethral cancer.
Risk factors
Factors that can increase the risk of renal cancer include:
The discovery of disease-specific biomarkers and the generation of high-quality antibodies are of great importance for the development of IVD immunoassays and kits. To assist customers in their IVD project development, Creative Biolabs offers a suite of IVD antibody development services against potential diagnostic biomarkers of renal cancer. We also offer IVD antibodies development services for many other diseases. If you are interested in our service, please feel free to contact us for more information and a detailed quote.
Our services target the following biomarkers for renal cancer diagnosis:
For Research Use Only.
